U-M Rogel Cancer Center

Recent papers from U-M Rogel Cancer Center

1. Roadmap for inferring metabolic regulation using multiomics, machine learning, and genome-scale modelingnpj Metabolic Health and Disease · 2026
2. Increasing cancer stemness drives prostate cancer progression, plasticity, therapy resistance and poor patient survivalMolecular Cancer · 2026
3. Circulating tumor cells in lobular versus ductal metastatic breast cancerBreast Cancer Research and Treatment · 2026
4. Keratin 9 regulates mechanosensitive YAP1 signalling in palmoplantar epidermisNature Cell Biology · 2026
5. The rise of reducing reagent-resistant TfR1 dimer marks ferroptosisNature Cell Biology · 2026
6. Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in miceNature Communications · 2026
7. Molecular Diagnosis of Melanocytic Neoplasia: Updates and ChallengesCancers · 2026
8. Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective StudyJournal of the National Comprehensive Cancer Network · 2026
9. Digital and Coaching Interventions for Uptake of Cancer Genetic TestingJAMA Network Open · 2026
10. Clinicopathological Characteristics of Merkel Cell Carcinoma in Younger PatientsThe American Journal of Surgical Pathology · 2026
11. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast CancerJournal of Clinical Oncology · 2026
12. RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical TrialJournal of Clinical Oncology · 2026
13. Inferring clinically relevant molecular subtypes of pancreatic cancer from routine histopathology using deep learningCommunications Medicine · 2026
14. Unlocking 30-Year-Old Archival Formalin-Fixed Paraffin-Embedded Breast Cancer Specimens (SWOG S8897): An Analytical Feasibility StudyJCO Precision Oncology · 2026
15. RNF5 Regulates HERP1 and OS9 Stability and Modulates Processing of an ERAD SubstrateLife · 2026
16. PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJAMA Oncology · 2026
17. Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T CellsCancers · 2026
18. Patient-centred and fit-for-purpose clinical trials in rare cancers: lessons from sarcomas for operationalising 2024 WHO Guidance and ICH E6(R3)EClinicalMedicine · 2026
19. USP15 regulates mitotic fidelity, metastatic potential, and chemotherapeutic response in ovarian cancer cellsMolecular Therapy Oncology · 2026
20. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AMLBlood · 2026